Therapeutic Applications

Cyclic Peptide Design for Autoimmune & Inflammatory Diseases

Explore cytokine and receptor interfaces, discover constrained peptide ligands, and connect potency with the exposure profile needed for sustained control of inflammatory signaling.

Discuss an Inflammation Program →
Conceptual illustration of a cyclic peptide at an immune-cell surface receptor amid inflammatory signaling
Application Overview

From Inflammatory Pathway to a Testable Peptide Hypothesis

Autoimmune and inflammatory diseases involve persistent signaling between immune cells and tissues. For a cyclic peptide program, the first question is which interaction should be interrupted: a cytokine binding its receptor, a receptor adopting an active state, or another accessible protein interface. A constrained peptide can present recognition groups in a defined geometry and probe surfaces that are difficult to address with conventional small molecules.

That biological opportunity creates a linked design task. The candidate must bind the intended target, distinguish related receptors or ligands, retain a useful conformation in biological media, and achieve exposure compatible with the clinical dosing goal. In a chronic disease program, the route of administration and frequency of dosing affect which chemical modifications should be explored. We organize these questions before making an extensive library or committing to a large analog series.

Our application-focused workflow connects target assessment, cyclic peptide discovery, computational optimization and experimental feedback. Projects can start from a target with structural and functional data, a screening hit with measured activity, or an established ring scaffold with a specific developability problem. Each entry point leads to a different first experiment and a different set of design priorities.

Featured Target Axis

IL‑23R Connects Molecular Design to Clinical Evidence

IL‑23 signaling is a clear example of an extracellular interaction that can be addressed by a receptor-binding peptide. The oral IL‑23R antagonist icotrokinra (formerly JNJ‑77242113) has demonstrated clinical activity in plaque psoriasis. In the phase 3 ICONIC-LEAD trial, week-16 IGA 0/1 responses were reported in 65% of the icotrokinra group and 8% of the placebo group; PASI 90 responses were 50% and 4%, respectively.1 The US FDA approved ICOTYDE (icotrokinra) in March 2026 for eligible adults and adolescents with moderate-to-severe plaque psoriasis.2

This development provides a practical framework for project planning. Receptor recognition and downstream functional antagonism need to be measured together. The peptide ring, noncanonical building blocks and solvent-exposed groups influence both receptor engagement and oral developability. An analog that improves one property is most useful when its effect on the remaining properties can be interpreted against a consistent parent comparator.

Questions for a New IL‑23R Series

  • Which receptor surface can be engaged without recreating an existing scaffold?
  • What ring size, topology and side-chain presentation preserve functional antagonism?
  • Can permeability and metabolic stability be improved while retaining the binding geometry?
  • Which exposure metric and tissue response should guide candidate selection?

Our IL‑23R patent analysis compares public scaffold and modification disclosures as a research resource.

Program Design

Four Research Questions Shape the Campaign

01

Is the Interface Accessible?

Review receptor architecture, ligand-contact regions, conformational states and available structures. Identify a tractable binding hypothesis and the assays that can distinguish receptor occupancy from functional blockade.

02

Which Scaffold Has a Useful Geometry?

Choose ring constraints, residue diversity and screening format around the target surface. Compare active hits by binding mode, sequence family and conformational behavior rather than potency alone.

03

Can the Molecule Reach Its Target?

Measure stability, solubility and route-specific exposure. For an oral program, incorporate gastrointestinal stability and permeability early; for other routes, prioritize systemic distribution and dosing interval.

04

Does Binding Change Biology?

Connect biochemical engagement to pathway inhibition, relevant cell readouts and selectivity. Establish how the cellular signal relates to the proposed disease mechanism and later in vivo studies.

Conceptual comparison of cyclic peptide scaffolds near a receptor surface
From Interface to Focused Scaffold SeriesConformationally distinct cyclic peptides can present different recognition groups to the same target surface. Comparing ring geometry and side-chain orientation helps select a small, diverse synthesis set.Binding and pathway assays then show which scaffold families merit further optimization for activity, selectivity and exposure.
AI and Computational Work

Where Modeling Adds Value

Target and Interface Assessment

Integrate experimental structures, sequence conservation and pathway knowledge to prioritize receptor surfaces. Analyze neighboring epitopes and related proteins to develop selectivity hypotheses. The output is an annotated interface map with candidate binding regions and measurable functional consequences.

Focused Library and Hit Design

Construct target-informed cyclic peptide libraries with controlled ring size, stereochemistry and side-chain diversity. Conformational sampling helps select candidates that present compatible binding groups while retaining scaffold diversity. When measured hits exist, the series can be expanded around observed structure–activity relationships.

Multi-Property Lead Optimization

Rank changes to sequence, N-methylation, side chains and ring closure against target interaction, selectivity, permeability, solubility and stability. A matched analog matrix separates the effect of each modification. Experimental outcomes then refine the next design round.

Exposure and Duration Design

Assess whether the desired dosing interval is limited by absorption, degradation, clearance or distribution. Where an active scaffold needs longer systemic residence, compare attachment sites and reversible albumin-binding appendages while monitoring free exposure and target potency.

Experimental Prioritization

Nominate a synthesis set with a parent peptide, activity controls and property controls. Pair binding studies with a pathway assay, then stage permeability, plasma stability and PK measurements according to the primary project decision.

Data-Driven Iteration

Bring measured activity and property data back into the series analysis. Highlight analogs with favorable combinations, identify conflicting readouts and design the next set to distinguish competing explanations. Results are reported with structures, assay context and clear selection criteria.

Integrated Workflow

A Five-Stage Application Workflow

The work progresses from a disease-relevant interaction to a candidate series with interpretable pharmacology and developability data.

1 · Target and mechanismDefine the cytokine–receptor axis, binding interface, disease hypothesis and functional endpoint.
2 · Scaffold discoveryBuild or select cyclic peptide libraries; nominate ring geometries and focused screening candidates.
3 · Joint optimizationImprove activity and selectivity alongside permeability, stability and synthetic tractability.
4 · Exposure designSelect route-specific property targets and assess half-life or albumin-binding options if needed.
5 · Functional validationConfirm identity, binding, pathway inhibition, ADMET properties and suitable PK endpoints.

For a target-led program, the first gate is an interface hypothesis supported by suitable binding and function assays. For a hit-led program, the first gate may be preservation of cellular activity after a ring or side-chain change. For a lead-led program, the first gate is often an exposure problem: poor permeability, insufficient stability or rapid clearance. The workflow keeps those distinct decisions visible while connecting them to one candidate profile.

Decision Criteria

Connect Molecular Readouts to Disease Biology

Inflammation programs can accumulate many positive assays without resolving whether a candidate is ready to advance. We define the decision use of each measurement at the outset. Target binding establishes recognition; a functional assay establishes whether the molecule changes signaling; route-specific property measurements establish whether sufficient active compound can reach the relevant compartment.

For IL‑23R, receptor binding and inhibition of IL‑23-driven cellular responses are complementary. A highly potent biochemical hit with low free exposure may require a different optimization path from a well-exposed analog with weak cellular antagonism. The comparison table keeps this distinction practical across a lead series.

Evidence layerProject questionDecision output
Target bindingDoes the cyclic peptide engage the intended receptor or interface?Affinity and selectivity profile with matched controls
Pathway functionDoes engagement inhibit the relevant inflammatory signal?Cellular potency, response shape and mechanism hypothesis
Physicochemical propertiesIs the candidate soluble and stable in the intended assay and dosing conditions?Developability profile and modification priorities
Oral absorptionCan an oral candidate survive and cross the intestinal barrier?Permeability, efflux and stability comparison
Systemic exposureDoes the active fraction persist over the intended interval?PK and free-exposure interpretation
Disease modelDo molecular and cellular effects translate into the selected biological setting?Integrated candidate nomination
Public Evidence and Research Context

What the IL‑23R Example Teaches

Clinical Translation

The FRONTIER phase 2 study reported a dose–response relationship for oral JNJ‑77242113 in moderate-to-severe plaque psoriasis, with week-16 PASI 75 response rates across active dose groups ranging from 37% to 79%, compared with 9% for placebo.3 Subsequent phase 3 results and the 2026 FDA approval established IL‑23R antagonism by an oral peptide as a concrete therapeutic application.1,2

For a new discovery program, the useful lesson is the alignment of receptor mechanism, oral exposure and disease-relevant endpoints. It guides which assays and molecular properties should be selected early, before the compound series grows.

Public Scaffold and Modification Space

Public applications WO2026067838A1, WO2026041110A1 and WO2026130480A1 describe IL‑23R-related peptide structures and variations that can be compared by ring architecture, side-chain presentation and appended groups.4–6 Their value for research planning is in the questions they expose: where can a scaffold be modified, which substitutions preserve function, and which changes alter exposure?

Read the three-application IL‑23R analysis for a closer structural comparison. A new project begins from its own target, compound and assay data rather than from a published example.

Project Outputs

Deliverables for a Target-Led or Lead-Led Program

Target and Assay Brief

Pathway map, receptor-interface hypotheses, comparator selection and a binding-to-function assay plan.

Scaffold and Library Proposal

Ring design rationale, diversity strategy, candidate structures and a prioritized screening or synthesis set.

Structure–Property Matrix

Matched analog comparison of target activity, selectivity, conformational behavior, permeability, stability and solubility.

Exposure Optimization Plan

Route-specific property goals, half-life design options and recommended free-exposure measurements.

Validation Package

Structural confirmation and staged biochemical, cellular, permeability, stability and PK experiments with controls.

Candidate Decision Report

Integrated evidence table, reasons for advancement or redesign and a focused next-round analog proposal.

Start a Program

Bring a Target, a Hit or a Lead Series

Share the inflammatory pathway, available target and assay data, peptide structures if known, and the desired route of administration. We can define a focused first phase that links molecular design to an interpretable biological decision.

Start an Inquiry →

References

  1. Bissonnette R, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393:1784–1795. doi: 10.1056/NEJMoa2504187.
  2. US Food and Drug Administration. Drug Trials Snapshots: ICOTYDE. Original approval date March 17, 2026.
  3. Bissonnette R, et al. An oral interleukin-23–receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390:510–521. doi: 10.1056/NEJMoa2308713.
  4. WO2026067838A1. Polypeptide compound and use thereof.
  5. WO2026041110A1. Polypeptide compound and use thereof.
  6. WO2026130480A1. Polypeptide compound and use thereof.

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.